Infective Microecology of Chemotherapy and Radiotherapy

  • Nong Xu
  • Chenyu Mao
Part of the Advanced Topics in Science and Technology in China book series (ATSTC)


This chapter mainly discusses the Mechanism of Chemotherapy and Radiotherapy, Chemotherapy and Radiotherapy Effect on Microecology, and Microecology of Infection Caused by Radiotherapy and Chemotherapy.


Nitrogen Mustard Molecular Target Agent Colonization Resistance Acneiform Rash Dermal Toxicity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Chabner B A, Longo D L. Cancer Chemotherapy and Biotherapy: Principles and Practice. 4th Ed.Philadelphia: Lippincott-Raven Inc, 2006.Google Scholar
  2. [2]
    Ma W W, Adjei A A. Novel agents on the horizon for cancer therapy. CA Cancer J Clin, 2009, 59: 111–137.CrossRefPubMedGoogle Scholar
  3. [3]
    Segal B H, Walsh T J, Gea-Banacloche JC, et al. Infections in the Cancer Patient. In: Cancer Principles & Practice of Ononlogy. 7th Ed. Philadelphia: Linppncott Williams & Wilking Inc, 2005.Google Scholar
  4. [4]
    Perry M C. Management of Drug Toxicy. 4th Ed. Philadelphia: Lippincott Williams & Wilkins Inc, 2008: 116–294.Google Scholar
  5. [5]
    Li T H, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Targ Oncol, 2009, 4: 107–119.CrossRefGoogle Scholar
  6. [6]
    Higa G M, Abraham J. Biological mechanisms of bevacizumab-associated adverse events. Exper Review of Anticancer Ther, 2009, 9: 999–1007.CrossRefGoogle Scholar
  7. [7]
    Anderson R, Jatoi A H, Robert C, et al. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist, 2009, 14: 291–302.CrossRefPubMedGoogle Scholar
  8. [8]
    Mundt A J, Roeske J C, Weichselbaum R R. Physical and biologic basis of radiation oncology. In: Cancer Medicine. 5th Ed. Philadelphia: Harcout Inc, 2000: 465–478.Google Scholar
  9. [9]
    Perez C A, Brady L W, Halperin E C, et al. Principles & Practice of Radiation Oncology. 4th Ed. Philadelphia: Lippincott Williams & Wilkins Inc, 2005.Google Scholar
  10. [10]
    Maschmeyer G, Haas A. The epidemiology and treatment of infections in cancer patients. Int J Antimicrob Agents, 2008, 31: 193–197.CrossRefPubMedGoogle Scholar
  11. [11]
    Bodey G P, Buckley M, Sathe Y S, et al. Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia. Ann Inteen Med, 1966, 61: 328–340.CrossRefGoogle Scholar
  12. [12]
    Mackall C l Fleisher T A, Brown M R, et al. Age, thymopoiesis and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med, 1995, 332: 143–149.CrossRefPubMedGoogle Scholar
  13. [13]
    Sun T, Tenenbaum M J, Greenspan J, et al. Morphologic and clinical observations in human infection with Babesia microti. J Infect Dis, 1983, 148: 239–248.CrossRefPubMedGoogle Scholar
  14. [14]
    Santos J I. Nutrition, infection and immunocompetence. Infec Dis Clin North Am, 1994, 8: 243–267.Google Scholar
  15. [15]
    Bochud P, Calandra T, Francioli P. Becteremia due to viridans streptococci in neutropenic patients: A review. Am J Med, 1994, 97: 256–264.CrossRefPubMedGoogle Scholar
  16. [16]
    Wells VD, Wong ES, Murray BE, et al. Infectios due to β -lactamaes producing, high-level gentamicin-resistant Enterococcus faecalis. Ann Intern Med, 1992, 116: 285–292.CrossRefPubMedGoogle Scholar
  17. [17]
    Walsh T J, Pizzo P A. Nosocomial fungal infections: a classification for hospital-acquired fungal infections and mycoses arising from endogenous flora or reactivation. Annu Rev Microbiol, 1988, 42: 517–545.CrossRefPubMedGoogle Scholar
  18. [18]
    Hughes W T, Armstrong D, Bodey G P, et al. From the infectious diseases society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis, 1990, 161: 3 81–396.CrossRefGoogle Scholar
  19. [19] NCCN practice guidelines for prevention and treatment of cancer related infections. 2009 v2.
  20. [20]
    Gridell C, Maione P, Amorosob D, et al. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: Results of an experts panel meeting. Crit Rev Oncol Hematol, 2008, 66: 155–162.CrossRefGoogle Scholar
  21. [21] NCCN practice guidelines for myeloid growth factors. 2011 vl.
  22. [22]
    Park J, Floch M H. Prebiotics, probiotics, and dietary fiber in gastrointestinal disease. Gastroenterol Clin North Am, 2007, 36: 47–61.CrossRefPubMedGoogle Scholar
  23. [23]
    Lenoir-Wijnkoop I, Sanders ME, Cabana MD, et al. Probiotic and prebiotic influence beyond the intestinal tract. Nutr Rev, 2007, 65: 469–489.CrossRefPubMedGoogle Scholar
  24. [24]
    Khani S, Hosseini H M, Taheri M, et al. Probiotics as an alternative strategy for prevention and treatment of human diseases: A review. Inflamm Allergy Drug Targets, 2012, 11: 79–89.CrossRefPubMedGoogle Scholar
  25. [25]
    Yan F, Polk D B. Probiotics and immune health. Curr Opin Gastroenterol, 2011, 27: 496–501.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Zhejiang University Press, Hangzhou and Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Nong Xu
    • 1
  • Chenyu Mao
    • 1
  1. 1.Department of Medical Oncology, the First Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouChina

Personalised recommendations